Health Canada / Santé Canada

Health Products and Food Branch / Direction générale des produits de santé et des aliments

TERMS AND CONDITIONS

Company: Novavax Inc.

Product: Nuvaxovid (SARS-CoV-2 recombinant spike protein)

Dossier ID: HC6-024-E255370

Background:

The Food and Drug Regulations allows the Minister to impose or amend terms and conditions, and request additional information, in relation to a COVID-19 drug submission, Drug Identification Number (DIN), or establishment license, at any time while it is in effect. In light of the severity of the COVID-19 pandemic, this allows the Minister to act quickly to gather important safety information or mitigate risk in a timely manner.

Depending on the requirement, terms and conditions can be ongoing (e.g., require a monthly report), have a defined time (e.g., a report is due to Health Canada on a specific day) or are to be completed once the data is available (e.g., a clinical trial is completed).

The status of the Terms and Conditions will be updated on a regular basis.

Status as of April 4, 2023

Table: Terms and Conditions

	Terms and Conditions	Issued	Status
1	Novavax Inc. is required to provide safety data for 6 months post initial vaccination from Study 2019nCoV-301, when the data become available.	February 17, 2022	Ongoing
2	Novavax Inc. is required to provide the results from the blinded crossover period including safety and efficacy data for 24 months from participants after the second dose from Study 2019nCoV-301, when the data become available.	February 17, 2022	Ongoing
3	Novavax Inc. is required to provide safety data for 6 months post initial vaccination from Study 2019nCoV-302, when the data become available.	February 17, 2022	Ongoing
4	Novavax Inc. is required to provide the results from the blinded crossover period including safety and efficacy data for 12 months from participants after the second dose from Study 2019nCoV-302, when the data become available.	February 17, 2022	Ongoing

5	Novavax Inc. is required to provide the safety, efficacy, and immunogenicity results from the adolescent participants from Study 2019nCoV-301, when the data become available.	February 17, 2022	Ongoing
6	Novavax Inc. is required to update the Product Monograph with information on the pregnancy registry, when the registry is in effect and the weblink is live. The text provided in the clarification request dated 2022-01-14 should be followed for this update.	February 17, 2022	Ongoing
7	Novavax Inc. is required to provide data regarding protection against current and emerging variants of concern, when available.	February 17, 2022	Ongoing
8	Provide submissions to Health Canada concerning changes to the manufacturing and control of drug substance and drug product (including adjuvant) as per recommendations in the Health Canada Post-NOC Guidance Document.	February 17, 2022	Ongoing
9	Provide the following to support the approval of the new master reference standard and the 1st working reference standard for relative potency assay: a) Data demonstrating comparability between the approved and proposed reference standards, as agreed upon during submission review; and b) Qualification protocol for future reference standards.	February 17, 2022	Ongoing
10	Provide data demonstrating comparable assay performance, as agreed upon during submission review, to support the approval of new testing facilities or major changes (including replacement) to current release tests for drug substance and drug product.	February 17, 2022	Closed
11	Provide data to support the approval of the use of Matrix-C batches manufactured at AGC-SEA for drug product formulation.	February 17, 2022	Ongoing
12	Provide the following updates from on-going stability studies for drug substance (DS), drug product (DP) and adjuvant lots manufactured using commercial processes at the approved facilities: a) Results at the end of approved shelf-lives for DS, DP and adjuvant as per the approved stability protocols and thereafter, on an annual basis; and b) Immediate notifications of Out-Of-Specification results for stability studies at the approved storage conditions.	February 17, 2022	Ongoing
13	Provide the final reports/summaries of shipping qualification studies to support the following: a) Transportation of drug product lots; and b) Transportation of adjuvant to drug product manufacturing site.	February 17, 2022	Closed

14	Provide the results from on-going extractables and leachables studies for the container closure systems of drug product and adjuvant, when available.	February 17, 2022	Ongoing
15	Provide a Certified Product Information Document (CPID) by May 31, 2022.	February 17, 2022	Closed
16	Provide the reagents, Standard Operating Procedures (SOP) and all associated documents for the transfer of relative potency assay to the Health Canada Lot Release Laboratories. Note that the document/s should clearly describe the dilution schemes used for the reference standard.	February 17, 2022	Ongoing
17	Novavax Inc. is required to treat adverse reactions associated with Nuvaxovid COVID-19 Vaccine (adjuvanted) (NVX-COV-2373) as priority and submit the corresponding reports to Health Canada without delay.	February 17, 2022	Ongoing
18	Novavax Inc. is required to submit Monthly Safety Summary Reports (MSSRs) for the first 6-months of marketing in Canada, unless otherwise determined by Health Canada. The MSSR should be submitted within 15 days after the last day of a month, beginning after the first full calendar month after authorization. These reports should contain the following: a) Actions taken in the reporting interval for safety reasons and changes to reference safety information; b) Estimated exposure and use patterns including doses distributed/ administered in the reporting interval / cumulative period, stratified by country, age groups, gender and dose. Should specific demographic data not be available, Novavax Inc. shall document this and provide an explanation in the MSSR; c) Reporting interval and cumulative number of adverse event reports in Canada and globally stratified by seriousness, age groups, gender, dose and in special populations (e.g. pregnant women). Should specific demographic data not be available, Novavax Inc. shall document this and provide an explanation in the MSSR; d) Reporting interval and cumulative number of reports per High Level Term (HLT) and System Organ Class (SOC); e) Overview of new/ ongoing/ closed signals during the reporting interval, and discussion of proposed risk minimization measures (if applicable); Reviews of safety topics identified by Health Canada and/ or foreign regulators; f) Updated list of Adverse Events of Special Interest (AESIs) from regulatory authorities, internationally recognized collaborations, and scientific literature. Summaries of reported cases of all AESIs and RMP safety concerns: numbers and relevant cases for the reporting	February 17, 2022	Closed

	interval/ cumulative period including complete evaluation, observed/ expected analyses, and causality assessment (if applicable); g) Fatal reports – reporting interval/ cumulative number of reports, including observed/expected analyses and discussion of relevant cases; h) Vaccination failure / lack of efficacy – reporting interval/ cumulative number of reports including discussion of confirmed and suspected cases, and variants of concern, if available; i) Medication errors – reporting interval and cumulative number of reports and discussion of relevant cases; j) Potential interaction with other vaccines/ concomitant treatments – reporting interval and cumulative number of reports of reports and discussion of relevant cases; and k) Overall risk/benefit consideration.		
19	Novavax Inc. is required to submit Periodic Safety Update Reports (PSURs)/ Periodic Benefit Risk Evaluation Reports (PBRERs) every 6 months, unless otherwise determined by Health Canada. The core PSUR/PBRER format should follow international guidance for COVID-19 vaccines.	February 17, 2022	Ongoing
20	Novavax Inc. is required to submit an updated core RMP with the Canadian Addendum in a timely manner if a safety issue is identified that requires immediate regulatory action or as requested by Health Canada. The RMP format should follow the guidance (Guidance Document Submission of Risk Management Plans and Follow-Up Commitments) and should include the following: a) A safety specification that details the identified risks, potential risks, and missing information for Nuvaxovid; b) A pharmacovigilance plan that details specific measures to be taken to identify and report safety issues in COVID-19 patients, including adverse reaction reporting, periodic reporting, and ongoing/planned studies; and c) A risk minimization plan, if applicable, to manage risks that may require additional measures beyond those considered standard (for instance, labelling).	February 17, 2022	Ongoing
21	Novovax Inc. to submit final snapshots of all components of the electronic platform (linked to any foreign or Canadian specific labels), containing the approved Canadian-specific information for Nuvaxovid in French and English for Health Canada's review and records, prior to launch of the electronic platform,	February 17, 2022	Ongoing

	and for each subsequent update.		
22	Novovax Inc. is requested to develop and distribute a Health Product Risk Communication (HPRC), in French and English, should a decision be made to import, for Canadian sites, non-Canadian labelled supplies. In this case, the HPRC would need to be developed with Health Canada approval and endorsement, to inform healthcare professionals that Novovax Inc. will delay implementation of Canadian-specific inner/outer labels following NDS-CV approval for Nuvaxovid, and that interim non Canadian inner/outer labels will be used for the short term. Please note the following: a) Novovax Inc. should include images and texts of these labels in the HPRC and clearly outline all deviations from Canadian requirements; b) The HPRC should direct healthcare professionals to the electronic platform where they can find information about the approved Canadian-specific labelling in both official languages; and c) The HPRC should include an alternative method for the health care professionals to obtain a paper copy of the HPRC and/or Product Monograph by mail or fax from Novovax Inc., if they cannot access the internet. Finally, Novovax Inc. should devise an appropriate dissemination strategy to ensure the HPRC reaches the intended audience in a timely manner.	February 17, 2022	Closed
23	Novovax Inc. to commit to developing Canadian specific bilingual labelling for Nuvaxovid and implementing such labelling once supplies are transitioned to Canadian dedicated supplies. Health Canada should be kept informed of estimated timelines and proposed strategies concerning the development and implementation of Canadian-specific bilingual labels. a) During the period prior to implementation of the Canadian-specific bilingual labeling, Canadian reference labels should be made available to healthcare professionals.	February 17, 2022	Ongoing
24	Novavax Inc. is required to submit Monthly Safety Summary Reports (MSSRs), unless otherwise determined by Health Canada. The MSSR should be submitted within 15 days after the last day of a month, beginning after the first full calendar month after authorization. These reports should contain the following: a) Actions taken in the reporting interval for safety reasons and changes to reference safety information; b) Estimated exposure and use patterns including doses distributed/ administered in the reporting interval/ cumulative period, stratified by country, age groups, gender and dose. Should specific demographic data not be available,	September 14, 2022	Closed

	Novavax Inc. shall document this and provide an explanation in the MSSR; a) Reporting interval and cumulative number of adverse event reports in Canada and globally stratified by seriousness, age groups, gender, dose and in special populations (e.g. pregnant women). Should specific demographic data not be available, Novavax Inc. shall document this and provide an explanation in the MSSR; b) Reporting interval and cumulative number of reports per High Level Term (HLT) and System Organ Class (SOC); c) Overview of new/ ongoing/ closed signals during the reporting interval, and discussion of proposed risk minimization measures (if applicable); Reviews of safety topics identified by Health Canada and/ or foreign regulators; d) Updated list of Adverse Events of Special Interest (AESIs) from regulatory authorities, internationally recognized collaborations, and scientific literature. Summaries of reported cases of all AESIs and RMP safety concerns: numbers and relevant cases for the reporting interval/ cumulative period including complete evaluation, observed/ expected analyses, and causality assessment (if applicable); e) Fatal reports – reporting interval/ cumulative number of reports, including observed/expected analyses and discussion of relevant cases; f) Vaccination failure / lack of efficacy – reporting interval/ cumulative number of reports including discussion of confirmed and suspected cases, and variants of concern, if available; g) Medication errors – reporting interval and cumulative number of reports and discussion of relevant cases; h) Potential interaction with other vaccines/ concomitant treatments – reporting interval and cumulative number of reports of reports and discussion of relevant cases; and i) Overall risk/benefit consideration.		
25	Final reports of Studies 2019nCoV-301 and 2019nCoV-501 should be provided once available.	November 17, 2022	Ongoing
26	Vaccine effectiveness following the booster vaccination with Nuvaxovid should be provided once the data become available.	November 17, 2022	Ongoing
27	Novavax Inc. is requested to develop and distribute a company-led customer communication, in English and French, should a decision be made to import non-Canadian labelled supplies for Canadian sites. The customer communication should aim to inform healthcare professionals that Novavax Inc. will delay the implementation of Canadian-specific inner/outer labels following NDS-CV approval for Nuvaxovid (SARS-CoV-2 recombinant spike protein), and that interim inner/outer labels will be used for the short term. Please note the following:	April 4, 2023	Ongoing

	a) Novavax Inc. should consider including images and texts of these labels in the customer communication and clearly outline all deviations from Canadian requirements; b) The customer communication should direct healthcare professionals to the electronic platform where they can find information about the approved Canadian-specific labelling in both official languages c) The customer communication should not resemble a Health Canada-endorsed Health Product Risk Communication and should not reflect a red banner at the top of the document. A company-led risk communication may take the form of a letter carrying the company letterhead, for example. The company-led customer communication does not require review by Health Canada; however, Novavax Inc. is welcome to seek courtesy feedback from BRDD. Novavax Inc. is expected to exercise due discretion to ensure prompt finalization and dissemination of the customer communication. Please provide a copy of the final, signed customer communication in English and French via eCTD once available.		